Enasidenib is an Oral IDH2 Mutant Enzymes Inhibitor for Myeloid Leukemia Research
Isocitrate dehydrogenase (IDH), one of the key enzymes in the citric acid cycle. And it catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG) generating carbon dioxide and NADPH/NADH. IDHs…